Sanofi stock dips on Trump vaccine order but growth outlook remains strong with raised 2026 sales guidance.
Sanofi's stock faced pressure after President Trump signed Executive Order 14420, which included recommendations on childhood vaccines. Despite this, Sanofi trades at a significant discount with a forward non-GAAP P/E ratio of 9.2x, well below the se...
